XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.1
MARKETABLE SECURITIES (Details Narrative)
 1 Months Ended 12 Months Ended
Jul. 16, 2018
USD ($)
shares
May 17, 2018
USD ($)
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2020
CAD ($)
Dec. 31, 2020
EUR (€)
Dec. 31, 2019
USD ($)
Jun. 30, 2019
Net unrealized loss on fair value investment     $ 2,246        
Marketable securities - Divsersa S.A. [Member]              
Closing price of shares | $ / shares     $ 5.45        
Shares issued as marketable securities | shares     40,000        
Marketable securities - National Bank of Greece [Member]              
Closing price of shares | $ / shares     $ 0.28        
Marketable securities     $ 4,609        
Shares issued as marketable securities | shares     16,666        
Stock issued during the period, amount     $ 218,183        
Marathon Global Inc [Member] | Distribution and Equity Acquisition Agreement [Member]              
Upfront cash received       $ 2,000,000      
Equity interest acquired description     a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services    
Agreement term     5 years 5 years 5 years    
Marathon Global Inc [Member] | Distribution and Equity Acquisition Agreement [Member] | Gross Sales One [Member]              
Cash received upon gross sales       $ 2,750,000      
Gross sales       13,000,000      
Marathon Global Inc [Member] | Distribution and Equity Acquisition Agreement [Member] | Gross Sales [Member]              
Cash received upon gross sales       2,750,000      
Gross sales       6,500,000      
Marathon Global Inc [Member] | Share Exchange Agreement [Member]              
Shares of Marathon transferred by company to KBB | shares 2,500,000            
Gain on exchange of investment $ 2,092,200 $ 1,953,000          
ICC [Member] | Share Exchange Agreement [Member]              
Net unrealized loss on fair value investment     $ 13,500        
Investement     $ 0     $ 33,000  
Upfront cash received       $ 2,000,000      
Equity method investment shares acquired | shares 5,000,000            
Description for ownership percentage The ten million shares of ICC owned by the Company constituted approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding. The Company does not have the ability to exercise significant influence over ICC   Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement    
Additional shares issued, shares | shares     3,000,000        
Additional shares issued, amount     $ 0        
Kaneh Bosm Biotechnology Inc [Member] | Share Exchange Agreement [Member]              
Transfer of shares | shares   2,500,000          
Kaneh Bosm Biotechnology Inc [Member] | Share Exchange Agreement [Member] | Canadian Securities Exchange [Member]              
Exchange of shares | shares   5,000,000          
May and July 2018 [Member] | Marathon Global Inc [Member]              
Consideration for the distribution services, shares     5,000,000        
Cosmo Farmacy LP [Member]              
Cash recognized           221,457  
Investement     $ 183,450     $ 163,575  
Initial share capital | €         € 150,000    
Initial share capital increased | €         500,000    
Pharmacy license value | €         € 350,000    
Maturity period of license     30 years 30 years 30 years    
Ownership equity             70.00%
cash contributed to limited partner | €         € 150,000    
Equity ownership remaining             30.00%